Coloplast A/S (Coloplast A/S) ROCE %

: 22.73% (As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Coloplast A/S's annualized ROCE % for the quarter that ended in Dec. 2023 was 22.73%.

Coloplast A/S ROCE % Historical Data

The historical data trend for Coloplast A/S's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coloplast A/S Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

ROCE %

Get a 7-Day Free Trial

65.91

69.67

69.32

30.40

22.27

Coloplast A/S Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															23.44	26.89	27.56	23.84	22.73

Coloplast A/S ROCE % Calculation

Coloplast A/S's annualized ROCE % for the fiscal year that ended in Sep. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Sep. 2023 )		(A: Sep. 2022 )		(A: Sep. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Sep. 2023 )		(A: Sep. 2022 )		(A: Sep. 2023 )
	=	953.533	/	( ( (4981.509 - 975.921)	+	(6891.967 - 2334.244) )	/ 2 )
	=	953.533	/	( (4005.588	+	4557.723)	/ 2 )
	=	953.533	/	4281.6555
	=	22.27 %

Coloplast A/S's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	1011.296	/	( ( (6891.967 - 2334.244)	+	(7109.352 - 2767.894) )	/ 2 )
	=	1011.296	/	( ( 4557.723	+	4341.458 )	/ 2 )
	=	1011.296	/	4449.5905
	=	22.73 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Coloplast A/S (OTCPK:CLPBY) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Coloplast A/S ROCE % Related Terms

Thank you for viewing the detailed overview of Coloplast A/S's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Coloplast A/S (Coloplast A/S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Coloplast A/S (OTCPK:CLPBY) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

CLPBF:USA COLOBc:UK 0QBO:UK COLO B:Denmark CBHD:Germany

Address

Holtedam 1-3, Humlebaek, DNK, DK-3050

Website

https://www.coloplast.com

Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, paste, powder, seals, and intermittent catheters for continence care. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.

Coloplast A/S (Coloplast A/S) Headlines

From GuruFocus

Coloplast A/S's Dividend Analysis

By GuruFocus Research • 12-07-2023